Business Context and Reporting Period
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney and metabolic diseases using its proprietary "Compass" platform. The company focuses on identifying genetic variants to drive drug discovery. This Form 10-K covers the fiscal year ended December 31, 2025. As of the filing date (March 25, 2026), the company is an Emerging Growth Company (EGC) and a non-accelerated filer.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| License Revenue | $0.0 | $167.5 |
| Net Loss / Income | $(131.1) | $52.2 |
| Research & Development Expenses | $108.4 | $83.5 |
| General & Administrative Expenses | $34.5 | $26.4 |
| Cash, Cash Equivalents, and Marketable Securities | $360.0 | $197.9 |
| Accumulated Deficit | $(489.5) | $(358.4) |
Liquidity: As of December 31, 2025, the company held $360.0 million in cash and marketable securities. Management believes this is sufficient to fund operations for at least one year from the filing date.
Material Changes vs. Prior Period
- Revenue Decline: License revenue dropped to $0 in 2025 from $167.5 million in 2024. The 2024 revenue was driven by one-time upfront payments from licensing agreements with Shionogi ($150M), Trace Neuroscience ($15M), and Neurocrine ($2.5M). No comparable revenue was recognized in 2025.
- Operating Loss: The company swung from a net income of $52.2 million in 2024 to a net loss of $131.1 million in 2025, primarily due to the absence of license revenue and increased operating expenses.
- Expense Growth: Total operating expenses increased by $33.0 million (30%) to $142.9 million. R&D expenses rose by $25.0 million due to increased headcount, stock-based compensation, and clinical trial costs for lead programs MZE829 and MZE782.
- Capital Raising: In 2025, the company completed its Initial Public Offering (IPO) in February (net proceeds ~$127.8M) and a Private Placement in September (net proceeds ~$141.3M).
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- MZE829 (APOL1-mediated Kidney Disease): In March 2026, the company reported positive topline Phase 2 data showing a mean 35.6% reduction in urinary albumin-to-creatinine ratio (uACR) in evaluable patients. The company plans to continue enrollment and advance to a pivotal program.
- MZE782 (PKU and CKD): Phase 1 results in healthy volunteers were reported in September 2025. The company plans to initiate two Phase 2 proof-of-concept trials in 2026.
- Partnerships: In March 2026, the company was notified that the first clinical development milestone for its Shionogi partnership (MZE001) was met, expecting a $20.0 million milestone payment.
Recent Financing (Subsequent Event)
In February 2026, the company entered into a Hercules Loan Agreement providing a senior secured term loan facility of up to $200.0 million. An initial tranche of $40.0 million was funded. The facility includes restrictive covenants and requires the maintenance of specific cash balances relative to outstanding debt unless market capitalization thresholds are met.
Key Risks
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to fund clinical trials and operations.
- Development Risk: As a clinical-stage company, there is no guarantee that therapeutic candidates will receive regulatory approval or achieve commercial success.
- Debt Covenants: The new Hercules Loan Agreement imposes financial covenants that could limit operating flexibility if not met.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $360M cash balance against the projected burn rate, considering the new $40M debt drawdown and upcoming Phase 2 trial costs.
- Debt Covenants: Review the specific financial covenants in the February 2026 Hercules Loan Agreement, particularly the requirement to maintain unrestricted cash equal to 50% of the outstanding loan amount if market cap is below $450M.
- Revenue Sustainability: Confirm the timeline for future milestone payments from Shionogi, Trace, and Neurocrine, as 2025 revenue was $0.
- Clinical Data: Review the full clinical data release for MZE829 Phase 2 to assess the statistical significance and safety profile beyond the topline summary.
- Dilution: Monitor the 2026 Open Market Sale Agreement (up to $200M) and outstanding pre-funded warrants (4.3M shares) for potential dilution.